Video

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

1: Safe administration and dosing of EGFR inhibitors in NSCLC - Practical guidance for oncology nurses

2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact, adherence challenges, and nursing management

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care

ASCO 2026: Lung cancer roundup

ASCO 2026: Comment: Multi-cancer earlier detection tests

Gedatolisib combinations double PFS vs alpelisib in PIK3CA-mutant advanced breast cancer

Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive mTNBC

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

ASCO 2026: Highlights and analysis

Velzatinib demonstrates broad activity across KIT mutations in advanced gastrointestinal stromal tumours